Paper · 41258799
Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment.
Manoukian P and 17 others. Cancer Res, 2026. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. Papers, record 41258799. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41258799
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Pancreatic Neoplasms | Major topic |
| Estrogens | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Humans | |
| Female | |
| Male | |
| Stromal Cells | |
| Prognosis | |
| Biomarkers, Tumor | |
| Cancer-Associated Fibroblasts |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 861196 | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) | PubMed | ||
| 848101012 | ZonMw (Netherlands Organisation for Health Research and Development) | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References73
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37,059,070 | Pancreatic cancer: Advances and challenges. | Cell | 2023 | https://conductscience.org/library/papers/37059070 | PubMed |
| 2 | 36,423,797 | Sex differences matter: Males and females are equal but not the same. | Physiol Behav | 2023 | https://conductscience.org/library/papers/36423797 | PubMed |
| 3 | 39,154,856 | Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. | Transl Res | 2024 | https://conductscience.org/library/papers/39154856 | PubMed |
| 4 | 34,518,665 | A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. | Nat Mater | 2022 | https://conductscience.org/library/papers/34518665 | PubMed |
| 5 | 40,508,010 | Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40508010 | PubMed |
| 6 | 33,495,315 | Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33495315 | PubMed |
| 7 | 37,269,289 | Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. | Cell Rep | 2023 | https://conductscience.org/library/papers/37269289 | PubMed |
| 8 | 38,781,719 | Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study. | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38781719 | PubMed |
| 9 | 15,583,024 | Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. | Endocr Rev | 2004 | https://conductscience.org/library/papers/15583024 | PubMed |
| 10 | 35,439,171 | An estrogen-sensitive fibroblast population drives abdominal muscle fibrosis in an inguinal hernia mouse model. | JCI Insight | 2022 | https://conductscience.org/library/papers/35439171 | PubMed |
1 to 10 of 73
See all 73 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,903,681 | From CAF subtypes to clinically relevant states: cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903681 | PubMed |
| 42,439,637 | Unveiling the Mysteries of CLEC3B: Physiological Roles, Pathological Impacts, and Research Gaps. | Cells | 2026 | https://conductscience.org/library/papers/42439637 | PubMed |
| 41,543,183 | <p>Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review)</p>. | Int J Oncol | 2026 | https://conductscience.org/library/papers/41543183 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CLEC3B | 7,123 | PubTator's text mining | https://conductscience.org/library/genes/7123 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41258799
GET https://conductscience.org/api/papers/v1/41258799/references?page=2